Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Accured Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Accured Expenses for 7 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 450.87% to $14.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 113.32% increase, with the full-year FY2025 number at $7.7 million, up 113.32% from a year prior.
  • Change in Accured Expenses was $14.3 million for Q4 2025 at Beam Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $70.4 million in Q4 2023 to a low of -$24.3 million in Q1 2024.
  • A 5-year average of $2.2 million and a median of $452500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 1359.38% in 2021, then crashed 7225.56% in 2024.
  • Beam Therapeutics' Change in Accured Expenses stood at $41.1 million in 2021, then crashed by 79.46% to $8.4 million in 2022, then skyrocketed by 733.84% to $70.4 million in 2023, then crashed by 105.79% to -$4.1 million in 2024, then surged by 450.87% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Change in Accured Expenses are $14.3 million (Q4 2025), $2.0 million (Q3 2025), and $9.9 million (Q2 2025).